Literature DB >> 10536171

Prospective long-term endoscopic and histologic follow-up of gastric lymphoproliferative disease of early stage IE low-grade B-cell mucosa-associated lymphoid tissue type following Helicobacter pylori eradication treatment.

A P Weston1, S K Banerjee, R T Horvat, M N Zoubine, D R Campbell, R Cherian.   

Abstract

Long-term endoscopic and histologic follow-up of Stage IE gastric lymphoproliferative disease of the low-grade B-cell mucosa-associated lymphoid tissue (MALT) type following cure of H. pylori was undertaken. Clinical and endoscopic features (age, race, endoscopic appearance, cure of H. pylori and duration of follow-up) were also evaluated as potential prognostic indicators for complete or near-complete regression of low-grade MALT lymphoma. Sixty-eight MALT lymphoma patients prospectively underwent H. pylori eradication. follow-up at periodic intervals with endoscopy and extensive mucosal biopsy protocol on 65 patients ranging from 12 weeks up to 73 months (mean +/- SD of 22.5+/-15.8 months) has been completed. H. pylori was eradicated in 89.2% of MALT lymphoma patients with complete histologic regression noted in 58.5%, near-complete regression in 18.5%, partial in 4.6%, and no change in 18.5%. Univariate analysis revealed two factors predictive of complete and/or near complete MALT lymphoma regression, H. pylori cure (p=0. 001) and duration of follow-up (p=0.001). Stepwise logistic regression also demonstrated that both H. pylori cure (p<0.0001) and duration of follow-up (p<0.02) were independently associated with complete and near complete MALT lymphoma regression. Age, race, and endoscopic appearance were not predictive of regression. We conclude that this lymphoproliferative disease predictably undergoes complete to near-complete histologic regression at variable rates following cure of H. pylori in a majority of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536171     DOI: 10.3892/ijo.15.5.899

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

Review 1.  Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Andriani; Francesca Cristofari; Chiara Bassanelli; Gian Paolo Spinelli; Silverio Tomao; Sergio Morini
Journal:  Med Oncol       Date:  2009-03-24       Impact factor: 3.064

2.  Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma.

Authors:  P F Ferrucci; A Vanazzi; C Crosta; G Pruneri; C Grana; M Bartolomei; G Paganelli; G Martinelli
Journal:  Ecancermedicalscience       Date:  2008-03-13

3.  Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan.

Authors:  Katsuya Sugizaki; Akira Tari; Yasuhiko Kitadai; Ichiro Oda; Shotaro Nakamura; Tadashi Yoshino; Toshiro Sugiyama
Journal:  Helicobacter       Date:  2018-03-04       Impact factor: 5.753

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.